Salix presents data to expand markets for bowel disorder drugs Xifaxan and Relistor
This article was originally published in Scrip
Executive Summary
After a subset analysis of two previously reported Phase III studies with positive results for Xifaxan (rifaximin) in the treatment of non-constipation irritable bowel syndrome, Salix Pharmaceuticals shared data at a conference in San Diego on 22 May showing no major differences in efficacy for men and women with IBS who were treated with the minimally absorbed antibiotic.